• Gaya Spolverato, Aslam Ejaz, Yuhree Kim, Malcolm H Squires, George A Poultsides, Ryan C Fields, Carl Schmidt, Sharon M Weber, Konstantinos Votanopoulos, Shishir K Maithel, and Timothy M Pawlik.
• Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD.
• J. Am. Coll. Surg.. 2014 Oct 1;219(4):664-75.

BackgroundReports on recurrence and outcomes of US patients with gastric cancer are scarce. The aim of this study was to determine incidence and pattern of recurrence after curative intent surgery for gastric cancer.Study DesignUsing the multi-institutional US Gastric Cancer Collaborative database, we identified 817 patients undergoing curative intent resection for gastric cancer between 2000 and 2012. Patterns and rates of recurrence along with associated risk factors were identified using adjusted regression analysis. Recurrences were classified as locoregional, peritoneal, or hematogenous.ResultsMedian patient age was 65.8 years (interquartile range [IQR] 56.4, 74.7); the majority of patients were male (n = 462, 56.6%) and white (n = 511, 62.5%). At the time of surgery, the majority of patients underwent a partial gastrectomy (n = 481, 59.2%) with a complete R0 resection achieved in 91.6% (n = 748) of patients. At the time of last follow-up, 244 (29.9%) of 817 patients developed a recurrence; 163 (66.8%) patients had recurrence at only a single site; the remaining 81 (33.2%) had multiple sites of initial recurrence. Among patients who recurred at a single site, recurrence was most common at a distant location and included hematogenous (n = 57, 23.4%) or peritoneal (n = 47, 19.3%) only metastasis. Tumors at the gastroesophageal junction (odds ratio [OR] 3.18, 95% CI 1.08 to 9.40; p = 0.04) were associated with higher risk of locoregional recurrence, while the presence of multiple lesions (OR 10.82, 95% CI 3.56 to 32.85; p < 0.001) remained associated with an increased risk of distant hematogenous recurrence after adjusted analysis. Recurrence was associated with worse survival, with a median recurrence-free survival of 10.8 months (IQR 8.9, 12.8) among those who experienced a recurrence.ConclusionsNearly one-third of patients experienced recurrence after gastric cancer surgery. The most common site of recurrence was distant.Copyright © 2014 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

23 keywords...

hide…